ATP6V0A4

Across TCGA pan-cancer cohorts, ATP6V0A4 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ATP6V0A4’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ATP6V0A4 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP6V0A4 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where ATP6V0A4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP6V0A4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.750	<.001	12	view →
HNSC	Male	All	−1.378	<.001	9	view →
LSCC	Male	All	−0.519	<.001	6	view →
LUAD	Male	III,IV	+0.643	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ATP6V0A4–CCRCC

Open the CCRCC breakdown →